PLL TX Australia

PLL TX Australia is a biotechnology company focused on the development of novel therapeutics for the treatment of fibrotic diseases. The company's primary research centers on the inhibition of prolyl-tRNA synthetase, an enzyme critical for the synthesis of proline-rich proteins like collagen, which are overproduced in fibrotic conditions. By targeting this pathway, PLL TX Australia aims to develop disease-modifying treatments for indications such as idiopathic pulmonary fibrosis and liver fibrosis. The entity operates as an Australian-based research and development arm, often associated with international collaborations in the tRNA synthetase field.